|
Su, Yingjun; Amiri, Katayoun I; Horton, Linda W et al. (2010) A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res 16:348-57
|
|
Dhawan, Punita; Su, Yingjun; Thu, Yee Mon et al. (2008) The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J Biol Chem 283:15399-408
|
|
Yang, Jinming; Pan, Wei-Hua; Clawson, Gary A et al. (2007) Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res 67:3127-34
|
|
Ueda, Yukiko; Su, Yingjun; Richmond, Ann (2007) CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Melanoma Res 17:91-103
|
|
Amiri, K I; Ha, H C; Smulson, M E et al. (2006) Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. Oncogene 25:7714-22
|
|
Yang, Jinming; Amiri, Katayoun I; Burke, James R et al. (2006) BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 12:950-60
|
|
Amiri, Katayoun I; Richmond, Ann (2005) Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev 24:301-13
|
|
Richmond, Ann; Fan, Guo Huang; Dhawan, Punita et al. (2004) How do chemokine/chemokine receptor activations affect tumorigenesis? Novartis Found Symp 256:74-89; discussion 89-91, 106-11
|
|
Amiri, Katayoun I; Horton, Linda W; LaFleur, Bonnie J et al. (2004) Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 64:4912-8
|
|
Amiri, Katayoun Izadshenas; Richmond, Ann (2003) Fine tuning the transcriptional regulation of the CXCL1 chemokine. Prog Nucleic Acid Res Mol Biol 74:1-36
|
Showing the most recent 10 out of 35 publications
